![[Adobe Stock]](https://sp-ao.shortpixel.ai/client/to_webp,q_glossy,ret_img,w_750,h_375/https://www.psypost.org/wp-content/uploads/2025/07/psilocybe-mushrooms-750x375.jpg)
A new study suggests that psilocybin—the psychedelic compound found in certain mushrooms—may do more than alter consciousness. Scientists report that psilocybin not only extends the lifespan of aging mice but also delays cellular aging in human cells. The research, which offers the first experimental evidence of psilocybin’s anti-aging effects, points to its potential as a treatment for age-related diseases and as a broader intervention to promote healthy aging.
The findings have been published in Nature Partnering Journal (NPJ) Aging.
Psilocybin is a naturally occurring psychedelic substance produced by mushrooms of the Psilocybe genus. When ingested, the compound is quickly converted in the body to psilocin, which interacts with serotonin receptors in the brain. These interactions are believed to produce the profound changes in perception and mood often associated with psychedelic experiences. In recent years, psilocybin has gained attention for its promising effects in treating depression, anxiety, and other mental health conditions. However, until now, little was known about how it might influence aging at a cellular or systemic level.
The researchers behind the new study, based at Emory University and Baylor College of Medicine, set out to explore whether psilocybin could affect biological markers of aging beyond the brain. They were motivated by a theory linking mental health and cellular aging, sometimes called the “psilocybin-telomere hypothesis.”
This hypothesis proposes that treatments improving mental well-being might also slow biological aging processes, such as the shortening of telomeres. Telomeres are the protective caps at the ends of chromosomes, and their erosion is associated with aging and the development of chronic diseases, including cancer and heart disease.
“A friend of mine had been asking me about psilocybin for months, which finally prompted me to spend some time reading what is known about it scientifically,” said study author Louise Hecker, an associate professor at Baylor College of Medicine. “I was immediately fascinated by how many different clinical indications it was being used for. One article posed a hypothesis that perhaps it is acting on telomeres, which could potentially explain its durable effects. I thought – I can test that!”
To investigate, the researchers used both laboratory-grown human cells and living mice. For the cell studies, they treated human lung and skin fibroblasts—cells responsible for producing connective tissue—with psilocin, the active form of psilocybin. These cells were grown in culture over time, and their rate of aging was monitored by measuring how many times they could divide before reaching senescence, a state where cells stop dividing. The team found that cells exposed to psilocin lived significantly longer than untreated cells. At a lower dose, psilocin extended cellular lifespan by 29 percent, while a higher dose resulted in a 57 percent increase.
Beyond lifespan extension, psilocin-treated cells also showed lower levels of stress-related markers. These cells had less oxidative stress, fewer signs of DNA damage, and greater preservation of telomere length compared to untreated cells. Molecular analysis revealed increased expression of SIRT1, a protein known to promote cell survival and regulate aging-related genes, and reduced levels of GADD45a, a marker of DNA damage. Collectively, the results suggested that psilocin not only delays cellular aging but does so by enhancing mechanisms involved in stress resistance and genetic stability.
The researchers then tested whether psilocybin could influence aging in living animals. They selected 19-month-old female mice—roughly equivalent to 60 to 65 human years—and administered psilocybin once per month for 10 months. The dosing regimen was designed to mimic protocols used in clinical trials for humans, adjusted to account for the faster metabolism in mice. The mice that received psilocybin had a significantly higher survival rate by the end of the study compared to those given a placebo. Eighty percent of the psilocybin-treated mice were still alive, compared to only 50 percent of the placebo group.
“Our study demonstrates, for the first time, that psilocybin has potent systemic impacts which can improve survival, even when administered late in life,” Hecker told PsyPost.
Although the researchers did not measure behavior or disease onset in detail, they reported that the treated mice appeared healthier, with improved fur quality and fewer signs of age-related decline. These observations, while preliminary, suggest that psilocybin’s benefits may go beyond lifespan and extend to overall health and physical condition.
“At the end of the experiment, the psilocybin-treated mice not only looked better than the vehicle-treated group, but they looked better than they did at the start of the experiment,” Hecker said.
The research also touches on broader public health concerns. In the United States, life expectancy has lagged behind other high-income countries, and chronic age-related illnesses remain a major burden.
Ali John Zarrabi, a co-investigator on the study and director of psychedelic research at Emory University, noted that the results have implications for how aging is managed. “This study provides strong preclinical evidence that psilocybin may contribute to healthier aging — not just a longer lifespan, but a better quality of life in later years,” he said. “As a palliative care physician-scientist, one of my biggest concerns is prolonging life at the cost of dignity and function. But these mice weren’t just surviving longer — they experienced better aging.”
While the study’s findings are promising, the authors caution that more research is needed before psilocybin could be used as an anti-aging therapy in humans. The experiments were conducted under tightly controlled conditions and involved a relatively small number of mice. Only female mice were included, which helped avoid variability linked to sex-based biological differences but also limits the generalizability of the results. Future studies will need to test whether the same effects occur in male mice, in other species, and eventually in people.
There are also questions about the long-term safety of psilocybin, particularly with repeated dosing. Although the researchers did not observe any signs of cancer or unchecked cell growth in the treated cells, extending the lifespan of cells without appropriate checks could, in theory, increase the risk of malignancies. The authors stress that future studies should investigate whether long-term psilocybin use has any influence on cancer development.
“This is only the first study to evaluate the impacts of psilocybin on aging,” Hecker noted. “”Many more questions still need to be answered: Are there sex-specific differences in efficacy? What is the optimal treatment protocol (ex dose, frequency)? Are there potential adverse effects associated with long term psilocybin treatment?”
The legal status of psilocybin remains another challenge. As a Schedule I substance under federal law in the United States, access to psilocybin for research purposes is tightly regulated, and funding for such studies is limited. These restrictions have slowed the pace of scientific exploration, even as early results suggest wide-ranging benefits.
Despite these hurdles, interest in psilocybin’s therapeutic potential is growing. The United States Food and Drug Administration has granted “breakthrough therapy” status to psilocybin for depression, a designation that signals its potential for substantial clinical benefit. Dozens of clinical trials are currently underway to test psilocybin for conditions ranging from anxiety to chronic pain.
Looking forward, Hecker hopes “to determine the optimal dosing regimen and monitor the potential for adverse effects at the pre-clinical level for successful clinical translation,” Hecker said. “This is a new frontier in psilocybin research! Psilocybin holds great potential as a novel anti-aging intervention. I hope this study sparks many more studies to better understand the potential of psilocybin for aging and age-related diseases.”
The study, “Psilocybin treatment extends cellular lifespan and improves survival of aged mice,” was authored by Kosuke Kato, Jennifer M. Kleinhenz, Yoon-Joo Shin, Cristian Coarfa, Ali J. Zarrabi, and Louise Hecker.